This is a routine cross-listing compliance filing. Ignore for trading purposes, the relevant financial data was already disclosed in the August 5 earnings release. Monitor the next catalyst: Phase 3 MANGROVE data and regulatory submissions for BRUKINSA in first-line MCL expected in 2H 2026.
Drug in focus
ONC drug pipeline →Ziihera
● Neutral Named in this 8-K- Impact
- Phase
- Approved
- Time to market
- Already approved and marketed. First FDA approval was November 2024 (BTC), second was August 2026 (GEA).
- Next catalyst
- None dated
What to watchZiihera is already approved in two indications (BTC and GEA) and generating royalty revenue through partners Jazz and BeOne. The next major catalyst would be a potential regulatory filing for HER2+ colorectal cancer following the August 2026 Breakthrough Therapy Designation, but no PDUFA date has been set. Watch for quarterly royalty revenue growth and any label expansion filings as the key value drivers.
How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+20- T+0 · Aug 26 $375.80entry
- T+1 · 3mo ago −0.88%α −1.54% · $372.49
- T+5 · 3mo ago −3.73%α −3.61% · $361.78
- T+20 · 8w ago −2.70%α −3.90% · $365.67
- T+57 · todayOpen
- T+60 · in 2d Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
BeOne Medicines filed its STAR Market interim report (H1 2026) in China, disclosing R&D spending breakdown by key product in accordance with PRC GAAP. The filing is a routine dual-listing disclosure requirement, not a standalone earnings release. It provides incremental transparency on pipeline investment allocation but contains no new financial results or guidance beyond what was released in the Q2 2026 earnings report on August 5, 2026.
Key Facts
- Filed PRC GAAP-based interim report with Shanghai Stock Exchange STAR Market for H1 2026
- Disclosed R&D expenses allocated by key products: BEQALZI ($74M), tacabrutideg ($44M), BRUKINSA ($43M), TEVIMBRA ($37M), BGB-43395 ($23M)
- Total U.S. GAAP R&D spend for H1 2026: $1.15B (vs $1.01B in H1 2025)
- Material accounting differences between PRC GAAP and U.S. GAAP on share-based compensation, income taxes, and leasing
- No new financial results, guidance, or business updates beyond August 5, 2026 earnings
Financial Impact
No material financial impact, this is a disclosure compliance filing with no new economic data
Risk Factors
- No new information risk, stock should not move on this filing
- Potential confusion if market misreads as a separate earnings release
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001651308-26-000025 |
| Document: 0001651308-26-000025-index.html | 0001651308-26-000025 |
| Document: 0001651308-26-000025.txt | 0001651308-26-000025 |
| 8-K Data (Synthetic) | 0001651308-26-000025 |
Track record
27 reports on ONC
3 of 7 bullish or bearish reports moved the stock their way by T+5. Best: +12.55% at T+60 after the Aug 5, 2026 report. 4 of 7 went positive at some point.
Filters
- Nov 13, 20263d ago SC 13G/A Neutral 2/10 Entry $416.54 Now $411.29 −1.26% settles Nov 23
- Nov 10, 20266d ago Insider Cluster Neutral 3/10 Entry $419.98 Now $411.29 −2.07% settles Nov 18
- Nov 6, 202610d ago 144 Neutral 2/10 Entry $417.33 to $411.29 Now $411.29 −1.45% ▼ −1.45% +0.25% vs SPY
- Nov 5, 202611d ago 144 Neutral 2/10 Entry $406.96 to $416.54 Now $411.29 +1.06% ▲ +2.35% −0.24% vs SPY
- Nov 5, 202611d ago 8-K Bullish 6/10 Entry $387.25 to $415.96 Now $411.29 +6.21% ▲ +7.41% +4.12% vs SPY
- Nov 4, 202612d ago Institutional Cluster Neutral 3/10 Entry $377.78 to $419.98 Now $411.29 +8.87% ▲ +11.17% +12.08% vs SPY
- Oct 2, 20266w ago Insider Cluster Bearish 5/10 Entry $361.65 to $350.40 Now $411.29 −13.73% ▲ +3.11% +3.53% vs SPY
- Sep 22, 20267w ago Institutional Cluster Mixed 4/10 Entry $368.08 to $365.27 Now $411.29 +11.74% ▼ −0.76% +0.42% vs SPY
- Sep 10, 20269w ago Insider Cluster Neutral 3/10 Entry $346.51 to $350.84 Now $411.29 +18.69% ▲ +1.25% +1.47% vs SPY
- Sep 3, 202610w ago Insider Cluster Neutral 2/10 Entry $358.26 to $353.83 Now $411.29 +14.80% ▼ −1.24% −0.03% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers